Kabanat — Cabazitaxel 60 mg
Kabanat is a next-generation taxane chemotherapy drug. Active ingredient: Cabazitaxel (60 mg).
Manufacturer: Natco Pharma (India). It is a generic equivalent of Jevtana.
Mechanism of Action:
Kabanat works by disrupting the microtubule network in cells, which is essential for mitotic and interphase cellular functions. It promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, causing cancer cell death.
✅ Key Usage: Specifically designed for patients whose cancer has progressed despite previous treatment with Docetaxel.
Indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.
It is used in combination with prednisone or prednisolone for patients previously treated with a docetaxel-containing treatment regimen.
⚠️ For Intravenous (IV) Infusion Only. Hospital Use.
Regimen: Administered as a 1-hour IV infusion every 3 weeks.
Critical Pre-medication:
To reduce the risk of severe hypersensitivity reactions, the following must be administered at least 30 minutes prior to each infusion:
- Antihistamine (Dexchlorpheniramine or Diphenhydramine).
- Corticosteroid (Dexamethasone).
- H2 antagonist (Ranitidine).
Oral Steroids: Patient must take oral prednisone (10 mg daily) throughout treatment.
- Severe Neutropenia: Neutrophil count ≤ 1,500/mm³. Blood tests are mandatory before each cycle.
- Severe hepatic impairment (Liver failure).
- History of severe hypersensitivity reactions to Cabazitaxel or drugs formulated with Polysorbate 80.
Adverse reactions can be significant:
- Neutropenia: Severe drop in white blood cells (high risk of infection/sepsis). Prophylactic G-CSF may be required.
- Diarrhea: Can be severe and lead to dehydration.
- Fatigue and Asthenia.
- Hypersensitivity: Rash, flushing, or hypotension during infusion.
What Customers Say
No reviews yet
Your review can be the first!